diaDexus Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • diaDexus's estimated annual revenue is currently $4.3M per year.(i)
  • diaDexus's estimated revenue per employee is $155,000

Employee Data

  • diaDexus has 28 Employees.(i)
  • diaDexus grew their employee count by 0% last year.

diaDexus's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is diaDexus?

A Multi-Product Company Diadexus is a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, providing healthcare providers with actionable information for managing patients. We pioneered the testing of Lp-PLA2 (lipoprotein-associated phospholipase A2), a marker of vascular-specific inflammation that provides new information, over and above traditional risk factors measured in a lipid panel, and has over a decade of peer-reviewed literature validating this biomarker's utility. Our products are the only two FDA-cleared tests to measure Lp-PLA2: The PLAC® Test ELISA Kit first cleared by the FDA in 2003 and The PLAC® Test for Lp-PLA2 Activity cleared in December 2014. Our pipeline of advanced cardiac biomarkers includes biomarkers for heart failure, proADM, proET-1 and proANP. Each marker gives distinct, additive information for healthcare providers over currently available markers. Diadexus also provides services to pharmaceutical partners to address the need to incorporate biomarkers in clinical development. Our portfolio of advanced cardiac biomarkers is available to be paired with novel therapeutics in development for indications where cardiovascular risk information would provide valuable insights. This information can be used by pharmaceutical companies in targeting the appropriate patient population and understanding the potential long-term side effects for their therapeutics, potentially avoiding long-term follow up studies.

keywords:N/A

N/A

Total Funding

28

Number of Employees

$4.3M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

diaDexus News

2022-04-20 - STD Diagnostics Market Size, Outlook And Forecast | Abbott ...

... Alere/Biosite/Inverness, Axis-Shield, Beckman Coulter/Danaher, Becton Dickinson, Bio/Data, Decode Genetics, Diadexus.

2022-04-19 - Cardiac Biomarker Market: Everything You Need to Know ...

Professional Key players: Abbott, Roche Diagnostics, BG Medicine, Biomerieux, Critical Diagnostics, DiaDexus, Response Biomedical, Siemens Healthcare,...

2022-04-17 - Quest Diagnostics Announces Organizational Changes to Accelerate Growth and Drive Operational Excellence

... joining Quest he held leadership, business development and strategy roles in molecular diagnostics at SmithKline Beecham and diaDexus.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2M2833%$7M
#2
$4.1M28-3%N/A
#3
$2.8M28N/AN/A
#4
$5.3M28N/AN/A
#5
$2.8M28N/AN/A